首页> 外文OA文献 >Innovative strategies for tailoring therapy in cancer patient: pharmacogenetics and hormone therapy personalization in metastatic or locally advanced breast cancer patients treated with Exemestane

【2h】

Innovative strategies for tailoring therapy in cancer patient: pharmacogenetics and hormone therapy personalization in metastatic or locally advanced breast cancer patients treated with Exemestane

机译：为癌症患者量身定制治疗的创新策略：依西美坦治疗的转移性或局部晚期乳腺癌患者的药物遗传学和激素治疗个性化

页面导航

著录项
相似文献
相关主题

著录项

作者
Gagno Sara;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类
入库时间 2022-08-20 20:54:23

相似文献

外文文献
中文文献
专利

1. Palbociclib in combination with anastrozole or exemestane as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2-breast cancer in Germany: Interim results of the INGE-B phase 2 study [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：Palbociclib与Anastrozole或Exemestane相结合，作为德国当地先进，无法操作或转移性的HR + / Her2-乳腺癌患者的一线治疗：Inge-B期2研究的中期结果
2. A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study [J] . Yamamoto Yutaka, Iwata Hiroji, Ueno Takayuki, Japanese journal of clinical oncology. . 2018,第9期

机译：在Her2阳性局部晚期/转移性乳腺癌患者中，Hertuzumab患者的随机开放标签，腹部疗法试验，曲妥珠单抗和化疗：日本乳腺癌研究组-M05珍贵研究
3. Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy [J] . Madeline M. Cook, Luai Al Rabadi, Andy J. Kaempf, The oncologist . 2021,第2期

机译：先前用CDK4 / 6抑制剂治疗治疗的转移激素受体阳性乳腺癌患者的everolimus和exemestane治疗
4. Adjuvant Neutron Therapy in Complex Treatment of Patients with Locally Advanced Breast Cancer [C] . V. A. Lisin, V. V. Velikaya, Zh. A. Startseva, International Conference on Physics of Cancer : Interdisciplinary Problems and Clinical Applications . 2017

机译：佐剂中子治疗复杂治疗局部晚期乳腺癌患者
5. Treatment Interruption and Discontinuation of Hormone Therapy in Hormone Receptor-Positive Breast Cancer Patients [D] . Mao, Daqin . 2020

机译：激素受体阳性乳腺癌患者中的治疗中断与激素治疗中的中断和停止
6. Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting [O] . Daniele Generali, *, Filippo Montemurro, 2017

机译：依维莫司加依西美坦在晚期乳腺癌中的应用：BALLET研究在转移环境中未接受和接受化学治疗的患者中的安全性研究结果
7. A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study [O] . Yutaka Yamamoto, Hiroji Iwata, Takayuki Ueno, 2018

机译：在Her2-阳性局部晚期/转移性乳腺癌患者中，Hertuzumab患者的随机开放标签，腹部疗法试验，先前用Pertuzumab，Trastuzumab和化疗治疗：日本乳腺癌研究组-M05珍贵研究

Innovative strategies for tailoring therapy in cancer patient: pharmacogenetics and hormone therapy personalization in metastatic or locally advanced breast cancer patients treated with Exemestane

著录项

相似文献

相关主题

期刊订阅